Oncology 2014;87:30–39 DOI: 10.1159/000362604 Received: February 14, 2014 Accepted after revision: March 24, 2014 Published online: June 25, 2014
© 2014 S. Karger AG, Basel 0030–2414/14/0871–0030$39.50/0 www.karger.com/ocl
Clinical Study
Renal Toxicity Associated with Weekly Cisplatin and Gemcitabine Combination Therapy for Treatment of Advanced Biliary Tract Cancer Satoshi Kobayashi Makoto Ueno Shinichi Ohkawa Yoshihiro Goda Manabu Morimoto
Kuniyasu Irie
Division of Hepatobiliary and Pancreatic Oncology, Kanagawa Cancer Center, Yokohama, Japan
Key Words Toxicity · Tolerability · Renal failure · Cisplatin · Cholangiocellular carcinoma · Cholangiocarcinoma · Biliary tract cancer · Creatinine · Glomerular filtration rate Abstract Objective: A combination of weekly cisplatin plus gemcitabine is a new standard regimen for patients with advanced biliary tract cancer (BTC). This regimen does not require prolonged hydration schedules; however, the long-time safety profile has not been evaluated so far. In particular, the aim of this study was to evaluate the renal function during this regimen. Methods: We reviewed 79 consecutive patients with BTC who received the weekly cisplatin plus gemcitabine regimen. The incidence of adverse events was evaluated by CTCAE v4.0. Results: A total of 402 courses were administered. The median cumulative dose of cisplatin was 250 mg (range: 25–825). The renal function was exacerbated gradually throughout the treatment course. The incidence of a decreased glomerular filtration rate (GFR) at
© 2014 S. Karger AG, Basel 0030–2414/14/0871–0030$39.50/0 www.karger.com/ocl
Clinical Study
Renal Toxicity Associated with Weekly Cisplatin and Gemcitabine Combination Therapy for Treatment of Advanced Biliary Tract Cancer Satoshi Kobayashi Makoto Ueno Shinichi Ohkawa Yoshihiro Goda Manabu Morimoto
Kuniyasu Irie
Division of Hepatobiliary and Pancreatic Oncology, Kanagawa Cancer Center, Yokohama, Japan
Key Words Toxicity · Tolerability · Renal failure · Cisplatin · Cholangiocellular carcinoma · Cholangiocarcinoma · Biliary tract cancer · Creatinine · Glomerular filtration rate Abstract Objective: A combination of weekly cisplatin plus gemcitabine is a new standard regimen for patients with advanced biliary tract cancer (BTC). This regimen does not require prolonged hydration schedules; however, the long-time safety profile has not been evaluated so far. In particular, the aim of this study was to evaluate the renal function during this regimen. Methods: We reviewed 79 consecutive patients with BTC who received the weekly cisplatin plus gemcitabine regimen. The incidence of adverse events was evaluated by CTCAE v4.0. Results: A total of 402 courses were administered. The median cumulative dose of cisplatin was 250 mg (range: 25–825). The renal function was exacerbated gradually throughout the treatment course. The incidence of a decreased glomerular filtration rate (GFR) at
